NAUSEA MEDICINE MARKET ANALYSIS

Regional Analysis

• North America: U.S. and Canada
• Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
• Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
• Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
• Middle East:  GCC, Israel and Rest of Middle East
• Africa: South Africa, North Africa, and Central Africa

Global Nausea Medicine Market Regional Insights

• North America is the largest market for nausea medicine, accounting for a market share of over 30% in 2023. The high prevalence of cancer and gastrointestinal diseases in the region is the major driver for the market growth. Increasing geriatric population and the high adoption of over-the-counter (OTC) medications are also contributing to the market growth in North America. For instance, January 2023, according to American Cancer Society, about 1.9 Mn new cancer cases are expected to be diagnosed in the U.S. in 2023. Moreover, approximately 609,820 deaths from cancer are expected in the U.S. in 2023, which are about 1,670 deaths per day.
• Europe is the second-largest market for nausea medicine, accounting for a market share of over 25% in 2023. Rising incidence of cancer and gastrointestinal diseases in the region is driving the growth of the market. Increasing awareness about the benefits of nausea medicine and the favorable reimbursement policies are also contributing to the market growth in Europe.
• Asia Pacific is the fastest-growing market for nausea medicine, with a CAGR of over 15% during the forecast period. The high prevalence of gastrointestinal diseases and motion sickness in the region is the major driver for the market growth. Increasing disposable income and the growing demand for innovative and effective nausea medicines are also contributing to the market growth in Asia Pacific.